PHP316 The New Technology Cost-Effectiveness Checklist: Introducing A Practical Guideline For The Selection Of Health Technologies  by Calderon, MR et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A569
life expectancies in the world, has invested heavily in domestic R&D and gener-
ics manufacturing in response to the U.S. embargo, and has been successful with 
achieving marketing authorization in multiple countries for its biopharmaceutical 
products. In Iran, international sanctions have led the government to encourage 
domestic production, which supplies 70-90% of the market. A possible relaxing of 
sanctions pending a deal on Iran’s nuclear program may pave the way for a multi-
national presence and increasing access to life-saving medicines. ConClusions: 
In general, the lifting of economic sanctions is observed to have positive impact on 
innovative pharmaceuticals, from both market access and technology transfer per-
spectives. The imposition of sanctions, however, may open the opportunity for local 
manufacturing and industrial innovation. Regardless of commercial and broader 
economic consequences, the lack of access to innovative pharmaceuticals may 
compromise optimal health care delivery in those affected countries.
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objeCtives: The objective of this study was to assess implications of the recent 
update to Russia’s Essential Drugs List (EDL) and Seven Nosologies (VZN) on the 
access of the local pharmaceutical market in the context of various economic pres-
sures. Methods: This study was based on the review of current and past iterations 
of the EDL and VZN, various policy changes, as well as economic and health outcome 
indicators. In addition, a pragmatic literature review was undertaken to assess the 
impact of the EDL and VZN updates on the current market access environment in 
Russia. Results: The 2015 EDL, which was previously updated in 2012, includes an 
additional 50 therapies, some of which are reimbursed through the VZN. Five new 
molecules were included within the VZN, including treatments for hemophilia, a 
cure for Gaucher’s disease, and a second-line therapy for multiple myeloma, bring-
ing the total to 23 therapies since its implementation in 2008. The 2013 decision to 
delegate the financial responsibilities (tenders) and implementation of the VZN to 
regional authorities by January 2015 to alleviate federal burden, did not materialize 
as expected, mainly due to cost concerns. 67% of 608 EDL therapies are manufac-
tured domestically, which is a reflection of their evolving pharmaceutical access 
policy due to economic pressure; in addition, only 35% of the 20,000 INNs marketed 
in Russia are reimbursed at the federal or state level while the rest are paid out-
of-pocket. ConClusions: The expansion of the EDL and VZN have made some 
innovative therapies available to certain populations that were previously unable to 
access these high-cost treatments. In addition, due to economic uncertainties, laws 
have been enacted to restrict the admission of foreign drugs to state procurement 
if equivalent INNs are available through local manufacturers.
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bACkgRound: Immunization decision-making (IDM) is usually based on multiple 
sources of evidence. Health economics (HE) has become increasingly relevant in IDM 
as one aspect to be considered. Objective of this study was to generate a consensus 
among stakeholders on how to implement HE into IDM in Germany. Method: We 
conducted a systematic literature review in order to identify relevant methods and 
advantages of considering HE evidence in IDM. Furthermore, an overview of IDM 
in several European countries was compiled based on literature. The generated 
evidence was used to prepare a national stakeholder symposium in January 2015 
on which representatives from academia, politics, industry, administration and 
patient-support groups were able to discuss different options on how to implement 
HE into IDM. Results: Based on the literature review five core advantages from 
considering HE aspects in IDM were identified: (I) modelling of future vaccine related 
public health effects; (II) identification of the most efficient vaccination strategy; 
(III) identification of critical input parameter; (IV) budget-impact-analysis; and (V) 
decision-making based on an incremental cost-effectiveness threshold. A recently 
conducted survey showed that most European countries consider HE in IDM. This 
is done (a) most frequently via an informal appraisal, (b) rarely by using a cost-
effectiveness threshold (4 countries), and (c) never by applying multiple-criteria 
decision-analyses. After key-note lectures, group-works and panel discussions, the 
majority of stakeholders had the opinion that in Germany the core advantages of (I) 
to (III) should be taken into account and decisions should be derived from an infor-
mal appraisal. disCussion: Most of the invited stakeholders acknowledged the use 
of HE in IDM. There was consensus that in Germany a cost-effectiveness threshold 
is no option. However, HE might be considered in IDM to compare different vac-
cination strategies and highlight the potential (economic) benefits of vaccination.
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objeCtives: The institutionalization of health technology assessment (HTA) 
remains a major challenge for many countries. Normative, political and social vari-
ations across nations limit the transference of HTA institutionalization models 
that have been implemented elsewhere. The “Knowledge to action” (KA) model 
has proven to reduce the “evidence-practice” gap through a systematic method 
of linking evidence to implementation and monitoring processes. The objective of 
data infrastructure, and some companies are advanced than others in tackling this 
issue. ConClusions: All respondents believed that MEAs will be used more fre-
quently. Performance-based schemes, while more difficult to be put in practice, are 
expected to become critical in disease areas like oncology.
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bACkgRound: The increasing focus on healthcare costs, aging of populations and 
rising costs of drug development require an effective approach to ensure the rational 
uptake and diffusion of technologies by health systems. Health stakeholders want 
safe, appropriate and effective healthcare with enduring results at a reasonable cost, 
particularly in environments where resources are scarce. In spite of much research, 
methodologies and recommendations, a simple solution to make budget allocations 
or procurement decisions is still needed by many decision makers. AppRoACh: A 
user-friendly and read-do checklist could facilitate the assessment of cost-effec-
tiveness of technologies, particularly new, innovative high cost drugs. The aero-
nautical industry (pre-flight safety checklist), World Health Organization/Harvard 
School of Public Health (pre-surgical safety checklist) and public health services 
(pre-disaster or disease preparedness checklists) have successfully prevented 
and reduced air traffic accidents and morbidity and mortality secondary to sur-
gical interventions, diseases and natural disasters through the implementation 
of safety checklists. pRACtiCAl iMpliCAtions: In pharmacoeconomics, as in 
aviation, medicine and public health, a checklist can help ensure consistency and 
completeness in carrying out the complex technology selection task improving 
the decision maker´s communication and consistency of information and data, 
facilitating the decision-making process and determining the most cost-effective 
options. This checklist could also be a useful tool to negotiate value added services, 
managed-entry agreements and risk-sharing arrangements to reduce the cost of 
drugs. ConClusions: A generic “New Technology Cost-Effectiveness Checklist”, 
intended to be modified as needed to fit local requirements, could guide evidence-
based decisions in resource-limited settings. In turn, it may become the tool to 
reach the universal goals of patients, providers, payers and policy-makers to (1) get 
the best drug and technology quality at the lowest cost and with reasonable access, 
and (2) enhance healthcare partnerships and solutions towards improved individual 
and population health outcomes.
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objeCtives: Recently the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) 
have been introduced. The scale is supposed to assist decisions about value and 
cost-effectiveness of new cancer therapies. This is done by classifying therapeutic 
advances according to their relative clinical benefit according to pre-defined cri-
teria. The objective of the present study was to investigate the scale from a health 
economics perspective. Methods: We conducted a critical appraisal of the build-
ing blocks of the scale in order to assess potential limitations to using the instru-
ment to inform policy. Results: Several issues that makes the scale problematic 
were identified. Three key areas of concern were: ESMO-MCBS uses different scales 
depending on if the intent of the therapy of to be curative or not. It is impossible to 
compare two cancer treatments which both have effect on survival and quality of 
life if the intension of the two therapies are different, yet they would compete for the 
same resources within the health care system. The ranking used is created based on 
expert opinion. It is unclear how these rankings would relate to the preferences of 
the patients or the general public. The scale relies on clinical trials as the evidence 
base. What matters for reimbursement agencies, payers and health care providers 
is how well the new treatment opportunity performs in clinical practice, in relation 
to existing therapeutic alternatives. ConClusions: There are limitations to the 
ESMO-MCBS at present as a measure of value. One important aspect that would 
merit further study is to validate how well the scale is able to discriminate between 
more and less valuable therapies as perceived by reimbursement bodies, by for 
instance comparing the rankings of therapies according to ESMO-MCBS to rankings 
based on estimated gains in survival and quality-adjusted survival.
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objeCtives: The objective of this study was to analyze the impact of imposed 
and/or withdrawn economic sanctions on various countries on access to innova-
tive pharmaceuticals, market access, and health outcomes. Recent geopolitical and 
pharmaceutical market dynamics related to Russia, Cuba, and Iran. Methods: This 
study examined the current health care financing options and market access impli-
cations of pharmaceuticals in Russia, Cuba, and Iran in light of the introduction or 
removal of sanctions on these markets. Intellectual property regulations, healthcare 
financing and procurement options, and domestic R&D investment were the key 
metrics evaluated in this research. Results: Due to sanctions imposed, Russia has 
pivoted from nearly solely an importation pharmaceutical market, to developing 
relevant policy framework to provide preferential access to locally-manufactured 
products (both from foreign and local manufacturers). Cuba, with one of the highest 
